Patent Grant
9907681
The present invention relates generally to stents, and specifically to stents for anchoring within body lumens.
Stents are used for various cardiovascular applications, such as to keep coronary vessels open, to act as grafts in abdominal aortic aneurisms (“AAAs”), to anchor vena cava filters, or to act as a frame for aortic valves. Stents are generally cylindrical, conical, or bottle shaped, and are designed to exert a radial force towards the vessel in which they are implanted. The resulting friction force provides securement of the stent to the vessel, thereby preventing migration of the stent after implantation. Techniques for increasing stent securement include providing hooks or barbs, shaping the stent into a truncated cone, and protruding the stent struts.
Functional tricuspid regurgitation (FTR) is governed by several pathophysiologic abnormalities such as tricuspid valve annular dilatation, annular shape, pulmonary hypertension, left or right ventricle dysfunction, right ventricle geometry, and leaflet tethering. Treatment options for FTR are primarily surgical. The current prevalence of moderate-to-severe tricuspid regurgitation is estimated to be 1.6 million in the United States. Of these, only 8,000 patients undergo tricuspid valve surgeries annually, most of them in conjunction with left heart valve surgeries.
Some applications of the present invention provide an anchoring system, which comprises a radially-expandable stent, and typically one or more tissue anchors and one or more tethers that connect the stent to the one or more tissue anchors. The stent is configured to be implanted in a body lumen, such as a blood vessel. The stent typically lacks rotational symmetry, because some of the struts of a circumferential portion of the stent protrude outwardly and thereby define a polygonal shape, while the struts of another contiguous circumferential portion of the stent do not protrude outwardly and thereby define a cylindrical shape.
The circumferential portion with the outward protrusions exhibits higher securement forces with the wall of the body lumen than does the circumferential portion without the outward protrusions, thus allowing relative axial movement of the non-protruding circumferential portion while maintaining the stent as a whole secured in the body lumen. Such selective securement may relieve stresses in the stent frame resulting from cyclic loads applied to the stent (e.g., cyclic cardiac loads) at the one or more tether circumferential locations, thereby enabling higher fatigue endurance in the stent.
For some applications, when unconstrained in a radially-expanded state, the stent is generally tubular and shaped so as to define:
The outward protrusions of the higher-securement portion cause the higher-securement portion to apply greater securement forces against the body lumen wall than applied by the lower-securement portion, which lacks outward protrusions. Such selective securement allows relative axial reciprocating movement of struts of the lower-securement portion, while maintaining the stent as a whole secured in the body lumen. As described above, such selective securement may thus relieve stresses in the stent frame resulting from cyclic loads applied to the stent (e.g., cyclic cardiac loads) at the one or more tether circumferential locations, thereby enabling higher fatigue endurance in the stent, and reducing the risk of stent migration.
For some applications, the outward protrusions are rotationally-asymmetrically distributed around the circumference of the stent, when the stent is unconstrained in the radially-expanded state. Alternatively or additionally, for some applications, the outward protrusions are periodically distributed around the higher-securement circumferential portion, when the stent is unconstrained in the radially-expanded state. Typically, the outward protrusions are blunt, when the stent is unconstrained in the radially-expanded state. Thus, the securement is achieved using the stent struts themselves, without the need for additional features such as barbs or hooks which increase the crimp size of the stent without adding to radial stiffness. Additionally, because the outward protrusions are blunt, the implant may be less likely to cause body lumen dissection than if sharp anchoring elements were provided.
For some applications, struts of the stent are shaped so as to define a plurality of columnar struts and a plurality of circumferential stent meanders, coupled to the columnar struts at respective axial locations. Typically, each of the circumferential stent meanders is disposed around the entire circumference of the stent. A set of one or more of the circumferential stent meanders are shaped so as to define the outward protrusions at the respective outward circumferential locations around the higher-securement portion, when the stent is unconstrained in the radially-expanded state.
For some applications, when the stent is unconstrained in the radially-expanded state, at least one of the circumferential stent meanders is shaped so as to define (a) around the higher-securement portion, the outward protrusions (the circumferential stent meander may thus define a polygon if projected onto a plane perpendicular to a longitudinal axis of the stent), and (b) around the lower-securement portion, an arc of a circle if the circumferential stent meander is projected onto the plane perpendicular to the longitudinal axis of the stent. For some applications, exactly one, exactly two, exactly three, exactly four, or five or more of the circumferential stent meanders are thus shaped. In contrast, the other circumferential stent meanders do not define the outward protrusions, and thus define respective circles if projected onto the plane perpendicular to the longitudinal axis of the stent. The stent may be shaped to define other polygon-circular shape patterns (e.g., every x circumferential stent meanders may define outward protrusions, such as every second meander, or every third meander). For some applications, the lower-securement portion is generally shaped as a circumferential portion of a circular cylinder.
For some applications, the stent is shaped so as to define one or more (e.g., exactly one) tension-distributing elements, which (a) extend along at least a tether-distribution axial segment of the stent at the one or more tether circumferential locations, respectively, (b) define the one or more tether interfaces, respectively, and (c) are configured to distribute tension applied by the one or more tethers, respectively, along the tether-distribution axial segment.
There is therefore provided, in accordance with an application of the present invention, apparatus including:
a radially-expandable stent, which, when unconstrained in a radially-expanded state, is generally tubular and shaped so as to define:
one or more tissue anchors; and
one or more tethers having respective first longitudinal portions that are coupled to the one or more tether interfaces, respectively, and respective second longitudinal portions, different from the respective first longitudinal portions, which are coupled to the one or more tissue anchors, respectively.
For some applications, the stent is shaped so as to define one or more tension-distributing elements, which (a) extend along at least a tension-distribution axial segment of the stent at the one or more tether circumferential locations, respectively, (b) define the one or more tether interfaces, respectively, and (c) are configured to distribute tension applied by the one or more tethers, respectively, along the tension-distribution axial segment of the stent. For some applications, the tension-distribution axial segment axially coincides with the lower-securement axial segment. For some applications, the one or more tension-distributing elements and the stent are fabricated from a single unit. For some applications, each of the one or more tension-distributing elements has a circumferential arc of between 1 and 15 degrees, when the stent is unconstrained in the radially-expanded state. For some applications, an axial length of each of the tension-distributing elements equals at least 15% of an axial length of the stent. For some applications, the axial length of the stent is between 20 and 120 mm, and the axial length of each of the tension-distributing elements is between 10 and 120 mm, when the stent is unconstrained in the radially-expanded state.
For some applications, the lower-securement axial segment of the stent extends along at least 30%, such as at least 100%, of an axial length of the stent, when the stent is unconstrained in the radially-expanded state.
For some applications, an interior of the stent defines a right circular cylindrical shape having a radius, and the outward protrusions extend radially outward from the cylindrical shape by a distance equal to between 5% and 25% of the radius, when the stent is unconstrained in the radially-expanded state.
For some applications, the one or more tether interfaces are shaped so as to define one or more openings, respectively, through which the one or more tethers are respectively coupled.
For some applications, each of the one or more tethers includes an element selected from the group consisting of: one or more metal struts, one or more metal wires, one or more flexible biocompatible textiles, and one or more flexible bands. For some applications, each of the one or more tethers has a length of between 20 and 120 mm.
For some applications, at least one of the one or more tissue anchors includes a helical tissue anchor.
For some applications, the stent is a first stent, and at least one of the one or more tissue anchors includes a second generally tubular stent.
For any of the applications described above, the one more tether interfaces may include exactly one tether interface at exactly one tether circumferential location, and the one or more tethers may include exactly one tether having a first longitudinal portion that is coupled to the tether interface. For some applications, the tether circumferential location is circumferentially centered in the lower-securement circumferential portion. For some applications, the higher-securement portion extends circumferentially around at least 270 degrees of the circumference of the stent, when the stent is unconstrained in the radially-expanded state. For some applications, the exactly one tether interface is shaped so as to define one or more openings through which the exactly one tether is coupled.
For any of the applications described above, the outward protrusions may be rotationally-asymmetrically distributed around the circumference of the stent, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the outward protrusions may be periodically distributed around the higher-securement circumferential portion, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the outward protrusions may be blunt, when the stent is unconstrained in the radially-expanded state. Alternatively, for any of the applications described above, the outward protrusions may be shaped so as to define respective barbs, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the lower-securement portion may have a circumferential arc that equals at least 200% of an average of circumferential distances between circumferential midpoints of circumferentially-adjacent ones of the outward protrusions around the higher-securement portion, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the stent may include a plurality of columnar struts and a plurality of circumferential stent meanders coupled to the columnar struts at respective axial locations, and one or more of the circumferential stent meanders may be shaped so as to define the outward protrusions at the respective circumferential locations around the higher-securement portion, when the stent is unconstrained in the radially-expanded state. For some applications, when the stent is unconstrained in the radially-expanded state, at least one of the circumferential stent meanders is shaped so as to define (a) around the higher-securement portion, the outward protrusions, and (b) around the lower-securement portion, an arc of a circle if the circumferential stent meander is projected onto a plane perpendicular to a longitudinal axis of the stent. For some applications, at least one of the circumferential stent meanders is shaped so as to define the outward protrusions around the higher-securement portion circumferentially between one or more circumferentially-adjacent pairs of the columnar struts, when the stent is unconstrained in the radially-expanded state. For some applications, at least one of the circumferential stent meanders is shaped so as to define a plurality of apices, at least some of which are shaped so as to define the outward protrusions, when the stent is unconstrained in the radially-expanded state. For some applications, respective radii of the columnar struts are measured between respective inner surfaces of the columnar struts and a central longitudinal axis of the stent, and an average of respective distances between the central longitudinal axis and respective most-outward surfaces of the protrusions equals between 105% and 125% of an average of the radii, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the higher-securement portion may extend circumferentially around at least 270 degrees of the circumference of the stent, such as at least 300 degrees, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the higher-securement portion may extend circumferentially around no more than 300 degrees of the circumference of the stent, when the stent is unconstrained in the radially-expanded state.
There is further provided, in accordance with an application of the present invention, apparatus including:
a radially-expandable stent, which, when unconstrained in a radially-expanded state, is generally tubular and shaped so as to define:
a plurality of tissue anchors; and
a plurality of tethers having respective first longitudinal portions that are coupled to the plurality of tether interfaces, respectively, and respective second longitudinal portions, different from the respective first longitudinal portions, that are coupled the plurality of tissue anchors, respectively.
For some applications, the circumferential arcs of the lower-securement circumferential portions are equal to one another.
For some applications, the higher-securement circumferential portions have respective circumferential arcs that are equal to one another.
For some applications, the circumferential arcs of the lower-securement circumferential portions are equal to one another, and the higher-securement circumferential portions have respective circumferential arcs that are equal to one another.
For some applications, the stent is shaped so as to define a plurality of tension-distributing elements, which (a) extend along at least respective tension-distribution axial segments of the stent at the tether circumferential locations, respectively, (b) define the tether interfaces, respectively, and (c) are configured to distribute tension applied by the tethers, respectively, along the tension-distribution axial segments of the stent, respectively. For some applications, the tension-distribution axial segments axially coincide with the lower-securement axial segments, respectively. For some applications, the tension-distributing elements and the stent are fabricated from a single unit. For some applications, each of the tension-distributing elements has a circumferential arc of between 1 and 15 degrees, when the stent is unconstrained in the radially-expanded state. For some applications, an axial length of each of the tension-distributing elements equals at least 15% of an axial length of the stent. For some applications, the axial length of the stent is between 20 and 120 mm, and the axial length of each of the tension-distributing elements is between 10 and 120 mm, when the stent is unconstrained in the radially-expanded state.
For some applications, the lower-securement axial segment of the stent extends along at least 30%, such as at least 100%, of an axial length of the stent, when the stent is unconstrained in the radially-expanded state.
For some applications, an interior of the stent defines a right circular cylindrical shape having a radius, and the outward protrusions extend radially outward from the cylindrical shape by a distance equal to between 5% and 25% of the radius, when the stent is unconstrained in the radially-expanded state.
For some applications, the tether interfaces are shaped so as to define respective one or more openings through which the tethers are respectively coupled.
For some applications, each of the tethers includes an element selected from the group consisting of: one or more metal struts, one or more metal wires, one or more flexible biocompatible textiles, and one or more flexible bands. For some applications, each of the tethers has a length of between 20 and 120 mm.
For some applications, at least one of the tissue anchors includes a helical tissue anchor.
For some applications, the stent is a first stent, and at least one of the tissue anchors includes a second generally tubular stent.
For any of the applications described above, the stent, when unconstrained in the radially-expanded state, may be shaped so as to define a same number of the tether interfaces and the lower-securement portions. For some applications, the tether circumferential locations are circumferentially centered in the lower-securement portions, respectively.
For any of the applications described above, the outward protrusions may be rotationally-asymmetrically distributed around the circumference of the stent, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the outward protrusions may be periodically distributed around each of the higher-securement circumferential portions, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the outward protrusions may be blunt, when the stent is unconstrained in the radially-expanded state. Alternatively, for any of the applications described above, the outward protrusions may be shaped so as to define respective barbs, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, each of the circumferential arcs of the lower-securement circumferential portions may equal at least 200% of an average of circumferential distances between circumferential midpoints of circumferentially-adjacent ones of the outward protrusions around the higher-securement portions, when the stent is unconstrained in the radially-expanded state.
For any of the applications described above, the stent may include a plurality of columnar struts and a plurality of circumferential stent meanders coupled to the columnar struts at respective axial locations, and one or more of the circumferential stent meanders may be shaped so as to define the outward protrusions at the respective circumferential locations around the higher-securement portions, when the stent is unconstrained in the radially-expanded state. For some applications, when the stent is unconstrained in the radially-expanded state, at least one of the circumferential stent meanders is shaped so as to define (a) around the higher-securement portions, the outward protrusions, and (b) around the lower-securement portions, respective arcs of a circle if the circumferential stent meander is projected onto a plane perpendicular to a longitudinal axis of the stent. For some applications, at least one of the circumferential stent meanders is shaped so as to define the outward protrusions around the higher-securement portions circumferentially between one or more circumferentially-adjacent pairs of the columnar struts, when the stent is unconstrained in the radially-expanded state. For some applications, at least one of the circumferential stent meanders is shaped so as to define a plurality of apices, at least some of which are shaped so as to define the outward protrusions, when the stent is unconstrained in the radially-expanded state. For some applications, respective radii of the columnar struts are measured between respective inner surfaces of the columnar struts and a central longitudinal axis of the stent, and an average of respective distances between the central longitudinal axis and respective most-outward surfaces of the protrusions equals between 105% and 125% of an average of the radii, when the stent is unconstrained in the radially-expanded state.
The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
Reference is still made to
Stent 20 typically comprises a plurality of interconnected superelastic metallic struts 40. Stent 20 may be manufactured by expanding a laser-slotted metallic tube, by chemically etching a flat sheet, by shaping a single wire, by assembling individual wire elements, or by any other method of construction known in the art. Stent 20 typically comprises a metal, such as a shape-memory alloy, e.g., Nitinol.
Stent 20, when unconstrained in a radially-expanded state (i.e., no forces are applied to the stent by a delivery tool, wall of a body vessel, or otherwise), such as shown in
Outward protrusions 70 of higher-securement portion 64 cause higher-securement portion 64 to apply greater securement forces against the body lumen wall than applied by lower-securement portion 56, which lacks outward protrusions. Such selective securement allows relative axial reciprocating movement of struts 40 of lower-securement portion 56, while maintaining the stent as a whole secured in the body lumen. Such selective securement may thus relieve stresses in the stent frame resulting from cyclic loads applied to the stent (e.g., cyclic cardiac loads) at the one or more tether circumferential locations 52, thereby on the one hand enabling higher fatigue endurance in the stent, while on the other hand reducing the risk of stent migration.
Each of outward protrusions 70 is shaped so as to include a radially outward directional component. Optionally, each of the protrusions is shaped so as to additionally include an axial directional component, i.e., to point toward one end of the stent, typically pointing against the direction of axial force.
For some applications, as shown in
Typically, as shown in
For some applications, an axial length of lower-securement axial segment 58 is greater than an axial length of higher-securement axial segment 65, such as at least 10% greater, e.g., at least 30% or at least 50% greater. Typically, lower-securement axial segment 58 and higher-securement axial segment 65 partially axially overlap. For some applications, higher-securement axial segment 65 is aligned entirely axially within lower-securement axial segment 58 (although not circumferentially aligned therewith).
For some applications (configuration not shown), stent 20 includes a securement portion that does not axially overlap with either lower-securement axial segment 58 or higher-securement axial segment 65, and is typically located near the end of stent 20 opposite the end nearest the one or more tether interfaces 50.
For some applications, struts 40 are shaped so as to define a plurality of columnar struts 74 and a plurality of circumferential stent meanders 76 (defining a plurality of apices), coupled to columnar struts 74 at respective axial locations. Typically, each of circumferential stent meanders 76 is disposed around the entire circumference C of stent 20. For example, as perhaps may best seen in
A set 80 of one or more of circumferential stent meanders 76 are shaped so as to define outward protrusions 70 at respective outward circumferential locations 72 around higher-securement portion 64, when stent 20 is unconstrained in the radially-expanded state. For some applications, each of circumferential stent meanders 76 of set 80 defines a number of outward protrusions 70 equal to between 20% and 100% of the total number of apices of the stent meander around the entire circumference C of the stent, such as between 50% and 90%, e.g., 86% (12/14). For some applications, each of circumferential stent meanders 76 of set 80 defines between 3 and 20 of outward protrusions 70, such as between 6 and 14 of outward protrusions 70, e.g., 12 of outward protrusions.
For some applications, when stent 20 is unconstrained in the radially-expanded state, at least one of circumferential stent meanders 76 is shaped so as to define:
For some applications, when stent 20 is unconstrained in the radially-expanded state, at least one of circumferential stent meanders 76 is shaped so as to define outward protrusions 70 around higher-securement portion 64 circumferentially between one or more circumferentially-adjacent pairs 84 of columnar struts 74, such as between every circumferentially-adjacent pair of columnar struts 74 around higher-securement portion 64, as shown). For some applications, exactly one, exactly two, exactly three (as shown and described above), exactly four, or five or more of circumferential stent meanders 76 are thus shaped.
For some applications, outward protrusions 70 are cascaded around higher-securement portion 64.
For some applications, at least one of circumferential stent meanders 76 is shaped so as to define a plurality of apices 86, at least some of which are shaped so as to define outward protrusions 70, when stent 20 is unconstrained in the radially-expanded state.
For some applications, when stent 20 is unconstrained in the radially-expanded state, respective radii R of columnar struts 74 are measured between respective inner surfaces of columnar struts 74 and central longitudinal axis 82 of the stent. An average of respective distances D1 between respective most-outward surfaces 88 of outward protrusions 70 equals between 105% and 125% of an average of radii R. For applications in which stent 20 is shaped generally as a circular cylinder, radii R equal one another, and distances D1 typically equal one another. Alternatively or additionally, for some applications, when stent 20 is unconstrained in the radially-expanded state, outward protrusions 70 have a length P of at least 1 mm, no more than 5 mm, and/or between 1 and 5 mm, measured from an outer surface 90 of stent 20 other than at the protrusions. Further alternatively or additionally, for some applications, wherein an interior of stent 20 defines a right circular cylindrical shape having radius R, and outward protrusions 70 extend radially outward from the cylindrical shape by a distance equal to between 5% and 25% of radius R, when stent 20 is unconstrained in the radially-expanded state.
The dimensions of stent 20 may vary in order to fit the body lumen in which it is placed, according to the medical application. Typically, when unconstrained in the radially-expanded state, stent 20 has (a) an inner diameter D2 that equals about 10-30% larger than the inner diameter of the body lumen, and/or (b) axial length L1 that equals between 100% and 600% of inner diameter D2. For example, for applications in which stent 20 is configured to be implanted a vena cava for tethering anchor 30 at the tricuspid valve, such as described hereinbelow with reference to
Typically, inner diameter D2 is constant along the stent, i.e., the stent is not flared at either end.
For some applications, stent 20 is shaped so as to define one or more (e.g., exactly one) tension-distributing elements 94, which (a) extend along at least a tether-distribution axial segment 95 of stent 20 at the one or more tether circumferential locations 52, respectively, (b) define the one or more tether interfaces 50, respectively, and (c) are configured to distribute tension applied by the one or more tethers 34, respectively, along tether-distribution axial segment 95. For some applications, as shown, tether-distribution axial segment 95 axially coincides with lower-securement axial segment 58. Optionally, the one or more tension-distributing elements 94 and stent 20 are fabricated from a single unit.
For some applications, each of the one or more tension-distributing elements 94 has a circumferential arc A1 (labeled in
For some applications, lower-securement portion 56 has a circumferential arc A2 that equals at least 150% (e.g., at least 200%) of an average of circumferential distances D3 between circumferential midpoints 96 of circumferentially-adjacent ones 98 of outward protrusions 70 around higher-securement portion 64, when stent 20 is unconstrained in the radially-expanded state.
Reference is again made to
For some applications, each of the one or more tethers 34 comprises an element selected from the group consisting of: one or more metal struts, one or more metal wires, one or more flexible biocompatible textiles, and one or more flexible bands. For some applications, each of the one or more tethers 34 has a length of at least 20 mm, no more than 120 mm, and/or between 20 and 120 mm.
For some applications, at least one of the one or more tissue anchors 30 comprises a helical tissue anchor. For some applications, the helical tissue anchor comprises a generally helical shaftless tissue-coupling element 106 and, typically, a proximal head 108. For some applications, such as described in U.S. Provisional Application 61/750,427, filed Jan. 9, 2013, which is assigned to the assignee of the present application and is incorporated herein by reference, helical tissue-coupling element 106 has (a) a first axial thickness along a first axial portion of a shaftless helical portion of the helical tissue-coupling element, and (b) a second axial thickness along a second axial portion of the shaftless helical portion more distal than the first axial portion. The second axial thickness is greater than the first axial thickness. The first and second axial thicknesses are measured along a longitudinal axis of the helical tissue-coupling element.
Alternatively or additionally, the helical tissue-coupling element has (a) a first axial yield strength along the first axial portion, and (b) a second axial yield strength along the second axial portion (more distal than the first axial portion). The second axial yield strength is greater than the first axial yield strength. Further alternatively or additionally, the helical tissue-coupling element has (a) a first axial stiffness along the first axial portion, and (b) a second axial stiffness along the second axial portion (more distal than the first axial portion). The second axial stiffness is greater than the first axial stiffness.
For some applications, such as described in the above-mentioned '427 application, the helical tissue-coupling element 106 is shaped so as to define (a) a first surface along a first axial surface characteristic portion of the shaftless helical portion of the helical tissue-coupling element, which first surface has a first surface characteristic, and (b) a second surface along a second axial surface characteristic portion of the shaftless helical portion different from the first axial surface characteristic portion. The second surface has a second surface characteristic that is configured to inhibit rotation of the helical tissue-coupling element to a greater extent than does the first surface characteristic. The first surface characteristic may, for example, be a high level of smoothness.
For some applications, stent 20 is a first stent, and at least one of the one or more tissue anchors 30 comprises a second generally tubular stent. A similar two-stent configuration (albeit without the stent configurations described herein) is shown, for example, in FIG. 4C of PCT Publication WO 2013/011502, which is incorporated herein by reference. For some applications, the second stent is expanded in a portion of a second blood vessel of the patient, e.g., the superior vena cava, the inferior vena cava, the coronary sinus, or a hepatic vein, e.g., the left hepatic vein, the right hepatic vein, or the middle hepatic vein.
For some applications, as shown in
For some applications, tether circumferential location 52 is circumferentially centered in lower-securement circumferential portion 60, as shown in
Reference is now made to
In the configuration shown in
This configuration may be useful for applying tension to two sites to which the two anchors are coupled, such as two sites of the tricuspid valve. For example, this configuration may be used in combination with the anchor placement described with reference to, and shown in,
Reference is now made to
Stent 220 typically comprises a plurality of interconnected superelastic metallic struts 40, and may be manufactured as described hereinabove regarding stent 20. Stent 220, when unconstrained in a radially-expanded state (i.e., no forces are applied to the stent by a delivery tool, wall of a body vessel, or otherwise), such as shown in
Outward protrusions 70 of higher-securement portion 64 cause higher-securement portion 64 to apply greater securement forces against the body lumen wall than applied by lower-securement portion 56, which lacks outward protrusions. Such selective securement allows relative axial reciprocating movement of struts 40 of lower-securement portion 56, while maintaining the stent as a whole secured in the body lumen. Such selective securement may thus relieve stresses in the stent frame resulting from cyclic loads applied to the stent (e.g., cyclic cardiac loads) at tether circumferential locations 52, thereby enabling higher fatigue endurance in the stent.
For some applications, the circumferential arcs of lower-securement circumferential portions 60 are equal to one another. Alternatively or additionally, for some applications, higher-securement circumferential portions 66 have respective circumferential arcs that are equal to one another.
For some applications, stent 220, when unconstrained in the radially-expanded state, is shaped so as to define a same number of tether interfaces 50 and lower-securement portions 56. For some applications, tether circumferential locations 52 are circumferentially centered in lower-securement circumferential portions 60, respectively, as shown in
For some applications, struts 40 are shaped so as to define the plurality of columnar struts 74 and the plurality of circumferential stent meanders 76 coupled to columnar struts 74 at respective axial locations. Typically, each of circumferential stent meanders 76 is disposed around the entire circumference of stent 220. For some applications, when stent 220 is unconstrained in the radially-expanded state, at least one of circumferential stent meanders 76 is shaped so as to define (a) around higher-securement portions 64, outward protrusions 70, and (b) around lower-securement portions 56, respective arcs of a circle if the circumferential stent meander is projected onto a plane perpendicular to longitudinal axis 82 of stent 220.
As mentioned above, stent 220 may have any of the features of stent 20, described hereinabove with reference to
The configuration described with reference to
Reference is now made to
System 10 is used for adjusting a distance between first and second implantation sites by pulling to apply tension to or relaxing tether 34 and/or by applying tension to at least one of tissue anchor 30 and stent 20. Responsively, a distance between the leaflets of tricuspid valve 304 is adjusted to reduce and eliminate regurgitation through valve 304, and thereby, valve 304 is repaired. For some applications, tether 34 is pulled or relaxed by manipulating stent 20, as is described hereinbelow.
For some applications, stent 20 is advanced toward and expanded in a portion of an inferior vena cava 308 (such as shown in
Once distal end 323 of catheter 322 is disposed within atrium 306, an anchor-deployment tube 324 is extended from within catheter 322 beyond distal end 323 thereof and toward a first implantation site 330. Anchor-deployment tube 324 holds tissue anchor 30 and a distal portion of tether 34. For some applications, tube 324 is steerable, as is known in the catheter art, while for other applications, a separate steerable element may be coupled to anchor-deployment tube 324. Under the aid of imaging guidance, anchor-deployment tube 324 is advanced toward first implantation site 330 until a distal end thereof contacts cardiac tissue of heart 302 at first implantation site 330. Anchor-deployment tube 324 facilitates atraumatic advancement of tissue anchor 30 toward first implantation site 330. For such applications in which anchor-deployment tube 324 is used, stent 20 is compressed within a portion of tube 324.
As shown, first implantation site 330 comprises a portion of an annulus of tricuspid valve 304. Implantation site 330 typically comprises a portion of the annulus of valve 304 that is between (1) the middle of the junction between the annulus and anterior leaflet 314, and (2) the middle of the junction between the annulus and posterior leaflet 316, e.g., between the middle of the junction between the annulus and anterior leaflet 314 and the commissure between the anterior and posterior leaflets. That is, tissue anchor 30 is coupled to, e.g., screwed into, the fibrous tissue of the tricuspid annulus close to the commissure in between anterior leaflet 314 and posterior leaflet 316. Implantation site 330 is typically close to the mural side of valve 304. For such applications, the drawing together of first and second implantation sites 330 and 352 cinches valve 304 and may create a bicuspidization of tricuspid valve 304, and thereby achieve stronger coaptation between anterior leaflet 314 and septal leaflet 312.
As shown in
The physician rotates the anchor-manipulating tool from a site outside the body of the patient in order to rotate tissue anchor 30 and thereby screw at least a portion of tissue anchor 30 in the cardiac tissue. Alternatively, system 320 is provided independently of the anchor-manipulating tool, and anchor-deployment tube 324 facilitates implantation of tissue anchor 30 in the cardiac tissue. The physician rotates anchor-deployment tube 324 from a site outside the body of the patient in order to rotate tissue anchor 30 and thereby screw at least a portion of tissue anchor 30 in the cardiac tissue.
As shown in
For some applications, prior to pulling the portion of tether 34 that is disposed between tissue anchor 30 and distal end 323 of catheter 322, a mechanism that facilitates the application of a pulling force to tether 34 is fixed in place, as described in the above-mentioned '601 publication.
For some applications, catheter 322 is reversibly coupled to a proximal portion of tether 34 by being directly coupled to the proximal portion of tether 34 and/or catheter 322 is reversibly coupled to stent 20. For example, catheter 322 may be reversibly coupled to stent 20 by the stent's application of a radial force against the inner wall of catheter 322 because of the tendency of stent 20 to expand radially. Following implantation of tissue anchor 30, catheter 322 (or an element disposed therein) is then pulled proximally to apply tension to tether 34, which, in such an application, functions as a tensioning element. For some applications, catheter 322 pulls on stent 20 in order to pull tether 34. For other applications, catheter 322 pulls directly on tether 34. For yet other applications, a pulling mechanism pulls on tether 34, as is described with reference to
Pulling tether 34 pulls taut the portion of tether 34 that is disposed between tissue anchor 30 and distal end 323 of catheter 322. Responsively to the pulling of tether 34, at least the anterior and septal leaflets of tricuspid valve 304 are drawn together because the geometry of the annulus and/or of the wall of atrium 306 is altered in accordance with the pulling of tether 34 and depending on the positioning of tissue anchor 30.
For some applications, during the pulling of tether 34 by catheter 322, a level of regurgitation of tricuspid valve 304 is monitored. Tether 34 is pulled until the regurgitation is reduced or ceases. Once the physician determines that the regurgitation of valve 304 is reduced or ceases, and valve 304 has been repaired, the physician decouples catheter 322 from stent 20 disposed therein and/or from tether 34, and then retracts catheter 322 in order to expose stent 20. During the advancement of catheter 322 toward atrium 306, stent 20 is disposed within a distal portion of catheter 322 in a compressed state. Following initial retracting of catheter 322, stent 20 is exposed and is allowed to expand and contact a wall of inferior vena cava 308.
The techniques described with reference to
As described above, for some applications the techniques described herein are used to repair the tricuspid valve. The techniques described herein may also be used to repair the mitral valve of the patient, mutatis mutandis.
Reference is now made to
Unlike stents 20, 120, and 220, stent 420 is not shaped so as to define lower-securement portion 56. Thus, the portion of stent 420 that includes one or more tether interfaces 50 (e.g., exactly one tether interface 50) at one or more tether circumferential locations 52 (e.g., at exactly one tether circumferential location 52) provides the same level of securement to the body lumen as do the other portions of the stent.
When stent 420 is unconstrained in the radially-expanded state (i.e., no forces are applied to the stent by a delivery tool, wall of a body vessel, or otherwise), only a portion of circumferential stent meanders 76 (e.g., exactly one, exactly two, exactly three (as shown), exactly four, or five or more of circumferential stent meanders 76) are shaped so as to define one or more outward protrusions. For example, first, third, and fifth distal circumferential stent meanders 76A, 76C, and 76E may define outward protrusions 70, and thus define respective polygons if projected onto the plane perpendicular to longitudinal axis 82 of stent 420. In contrast, the other circumferential stent meanders may not define any outward protrusions 70, and thus define respective circles if projected onto the plane perpendicular to longitudinal axis 82 of stent 420. Stent 420 may be shaped to define other polygon-circular shape patterns (e.g., every x circumferential stent meanders 76 may define outward protrusions, such as every second meander, or every third meander). Such providing of lower-securement axial spaces between circumferential stent meanders may facilitate better tissue fixation by scattering the protrusions.
For some applications, when stent 420 is unconstrained in the radially-expanded state, at least one of circumferential stent meanders 76 is shaped so as to define outward protrusions 70 circumferentially between one or more circumferentially-adjacent pairs 84 of columnar struts 74, such as between every circumferentially-adjacent pair of columnar struts 74. For some applications, exactly one, exactly two, exactly three (as shown and described above), exactly four, or five or more of circumferential stent meanders 76 are thus shaped.
For some applications, outward protrusions 70 are cascaded around stent 420.
Reference is now made to
In this configuration, unlike the configurations shown in the other figures, outward protrusions 70 are shaped so as to define respective barbs 530, when stent 520 is unconstrained in the radially-expanded state (i.e., no forces are applied to the stent by a delivery tool, wall of a body vessel, or otherwise). The barbs may aid in securing higher-securement portion 64 of stent 520 to the vessel wall. The barbs may protrude from one or more of columnar struts 74 of higher-securement portion 64, as shown, or from one or more of circumferential stent meanders 76 of higher-securement portion 64 (configuration not shown).
Medical Applications
The anchoring system and stents described herein may be used for a number of different medical applications, including but not limited to the following applications. For some of these applications, tissue anchors 30 and tethers 34 are not provided.
As used in the present application, including in the claims, “tubular” means having the form of an elongated hollow object that defines a conduit therethrough. A “tubular” structure may have varied cross-sections therealong, and the cross-sections are not necessarily circular. For example, one or more of the cross-sections may be generally circular, or generally elliptical but not circular, or circular.
The scope of the present invention includes embodiments described in the following applications, which are assigned to the assignee of the present application and are incorporated herein by reference. In an embodiment, techniques and apparatus described in one or more of the following applications are combined with techniques and apparatus described herein:
In particular, the stents described herein may be used as one or more of the stents described in the above-listed applications, in combination with the other techniques described therein.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
The present application is the U.S. national stage of International Application PCT/IL2014/050233, filed Mar. 9, 2014, which claims priority from U.S. Provisional Application 61/783,224, filed Mar. 14, 2013, which is assigned to the assignee of the present application and is incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IL2014/050233 | 3/9/2014 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2014/141239 | 9/18/2014 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4214349 | Munch | Jul 1980 | A |
| 4405313 | Sisley et al. | Sep 1983 | A |
| 4423525 | Vallana | Jan 1984 | A |
| 4444207 | Robicsek | Apr 1984 | A |
| 4493329 | Crawford et al. | Jan 1985 | A |
| 4532926 | O'Holla | Aug 1985 | A |
| 4548202 | Duncan | Oct 1985 | A |
| 4602911 | Ahmadi et al. | Jul 1986 | A |
| 4625727 | Leiboff | Dec 1986 | A |
| 4712549 | Peters et al. | Dec 1987 | A |
| 4741336 | Failla et al. | May 1988 | A |
| 4778468 | Hunt et al. | Oct 1988 | A |
| 4808157 | Coombs | Feb 1989 | A |
| 4853986 | Allen | Aug 1989 | A |
| 5108420 | Marks | Apr 1992 | A |
| 5330521 | Cohen | Jul 1994 | A |
| 5336233 | Chen | Aug 1994 | A |
| 5350399 | Erlebacher et al. | Sep 1994 | A |
| 5450860 | O'Connor | Sep 1995 | A |
| 5473812 | Morris et al. | Dec 1995 | A |
| 5474518 | Farrer-Velazquez | Dec 1995 | A |
| 5776178 | Pohndorf et al. | Jul 1998 | A |
| 5792400 | Talja et al. | Aug 1998 | A |
| 5843120 | Israel | Dec 1998 | A |
| 5843164 | Frantzen et al. | Dec 1998 | A |
| 5904697 | Gifford et al. | May 1999 | A |
| 5948000 | Larsen et al. | Sep 1999 | A |
| 5957953 | DiPoto et al. | Sep 1999 | A |
| 5961440 | Schweich, Jr. et al. | Oct 1999 | A |
| 6010113 | Rotering | Jan 2000 | A |
| 6027523 | Schmieding | Feb 2000 | A |
| 6045497 | Schweich, Jr. et al. | Apr 2000 | A |
| 6050936 | Schweich, Jr. et al. | Apr 2000 | A |
| 6077214 | Mortier et al. | Jun 2000 | A |
| 6183512 | Howanec et al. | Feb 2001 | B1 |
| 6193734 | Bolduc et al. | Feb 2001 | B1 |
| 6206913 | Yencho et al. | Mar 2001 | B1 |
| 6210432 | Solem et al. | Apr 2001 | B1 |
| 6298272 | Peterfeso et al. | Oct 2001 | B1 |
| 6299635 | Frantzen | Oct 2001 | B1 |
| 6332893 | Mortier et al. | Dec 2001 | B1 |
| 6338738 | Bellotti et al. | Jan 2002 | B1 |
| 6402780 | Williamson, IV et al. | Jun 2002 | B2 |
| 6402781 | Langberg et al. | Jun 2002 | B1 |
| 6406420 | McCarthy et al. | Jun 2002 | B1 |
| 6461336 | Lane | Oct 2002 | B1 |
| 6533810 | Hankh et al. | Mar 2003 | B2 |
| 6537198 | Vidlund et al. | Mar 2003 | B1 |
| 6537314 | Langberg et al. | Mar 2003 | B2 |
| 6575976 | Grafton | Jun 2003 | B2 |
| 6585766 | Huynh et al. | Jul 2003 | B1 |
| 6602288 | Cosgrove et al. | Aug 2003 | B1 |
| 6613078 | Barone | Sep 2003 | B1 |
| 6613079 | Wolinsky | Sep 2003 | B1 |
| 6616684 | Vidlund et al. | Sep 2003 | B1 |
| 6619291 | Hlavka et al. | Sep 2003 | B2 |
| 6622730 | Ekvall et al. | Sep 2003 | B2 |
| 6626899 | Houser et al. | Sep 2003 | B2 |
| 6626930 | Allen et al. | Sep 2003 | B1 |
| 6629534 | St. Goar et al. | Oct 2003 | B1 |
| 6629921 | Schweich, Jr. et al. | Oct 2003 | B1 |
| 6641597 | Burkhart et al. | Nov 2003 | B2 |
| 6645193 | Mangosong | Nov 2003 | B2 |
| 6702846 | Mikus | Mar 2004 | B2 |
| 6709456 | Langherg et al. | Mar 2004 | B2 |
| 6718985 | Hlavka et al. | Apr 2004 | B2 |
| 6719767 | Kimblad | Apr 2004 | B1 |
| 6723038 | Schroeder et al. | Apr 2004 | B1 |
| 6730118 | Spenser et al. | May 2004 | B2 |
| 6743198 | Tihon | Jun 2004 | B1 |
| 6746472 | Frazier et al. | Jun 2004 | B2 |
| 6764510 | Vidlund et al. | Jul 2004 | B2 |
| 6776754 | Wilk | Aug 2004 | B1 |
| 6797001 | Mathis | Sep 2004 | B2 |
| 6810882 | Langberg et al. | Nov 2004 | B2 |
| 6884250 | Monassevitch | Apr 2005 | B2 |
| 6893459 | Macoviak | May 2005 | B1 |
| 6908478 | Alferness et al. | Jun 2005 | B2 |
| 6929660 | Ainsworth et al. | Aug 2005 | B1 |
| 6989028 | Lashinski et al. | Jan 2006 | B2 |
| 6997951 | Solem et al. | Feb 2006 | B2 |
| 7011682 | Lashinski et al. | Mar 2006 | B2 |
| 7018406 | Seguin et al. | Mar 2006 | B2 |
| 7018408 | Bailey et al. | Mar 2006 | B2 |
| 7037290 | Gardeski et al. | May 2006 | B2 |
| 7041097 | Webler | May 2006 | B1 |
| 7044967 | Solem et al. | May 2006 | B1 |
| 7056333 | Walshe | Jun 2006 | B2 |
| 7063711 | Loshakove et al. | Jun 2006 | B1 |
| 7077861 | Spence | Jul 2006 | B2 |
| 7083628 | Bachman | Aug 2006 | B2 |
| 7087064 | Hyde | Aug 2006 | B1 |
| 7094244 | Schreck | Aug 2006 | B2 |
| 7101395 | Tremulis et al. | Sep 2006 | B2 |
| 7101396 | Artof et al. | Sep 2006 | B2 |
| 7112219 | Vidlund et al. | Sep 2006 | B2 |
| 7125421 | Tremulis et al. | Oct 2006 | B2 |
| 7144363 | Pai et al. | Dec 2006 | B2 |
| 7159593 | McCarthy et al. | Jan 2007 | B2 |
| 7166127 | Spence et al. | Jan 2007 | B2 |
| 7169187 | Datta | Jan 2007 | B2 |
| 7175625 | Culbert | Feb 2007 | B2 |
| 7179282 | Alferness et al. | Feb 2007 | B2 |
| 7186262 | Saadat | Mar 2007 | B2 |
| 7189199 | McCarthy et al. | Mar 2007 | B2 |
| 7192442 | Solem et al. | Mar 2007 | B2 |
| 7192443 | Solem et al. | Mar 2007 | B2 |
| 7198646 | Figulla et al. | Apr 2007 | B2 |
| 7201772 | Schwammenthal | Apr 2007 | B2 |
| 7211107 | Bruckheime et al. | May 2007 | B2 |
| 7211110 | Rowe et al. | May 2007 | B2 |
| 7241257 | Ainsworth et al. | Jul 2007 | B1 |
| 7247134 | Vidlund et al. | Jul 2007 | B2 |
| 7258697 | Cox | Aug 2007 | B1 |
| 7291168 | Macoviak et al. | Nov 2007 | B2 |
| 7311697 | Osborne | Dec 2007 | B2 |
| 7311728 | Solem et al. | Dec 2007 | B2 |
| 7316706 | Bloom et al. | Jan 2008 | B2 |
| 7316710 | Cheng et al. | Jan 2008 | B1 |
| 7329279 | Haug et al. | Feb 2008 | B2 |
| 7331972 | Cox | Feb 2008 | B1 |
| 7335213 | Hyde et al. | Feb 2008 | B1 |
| 7338506 | Caro | Mar 2008 | B2 |
| 7351256 | Hojeibane | Apr 2008 | B2 |
| 7371244 | Chatlynne et al. | May 2008 | B2 |
| 7374573 | Gabbay | May 2008 | B2 |
| 7381210 | Zarbatany et al. | Jun 2008 | B2 |
| 7381220 | Macoviak et al. | Jun 2008 | B2 |
| 7390329 | Westra et al. | Jun 2008 | B2 |
| 7431692 | Zollinger et al. | Oct 2008 | B2 |
| 7431726 | Spence et al. | Oct 2008 | B2 |
| 7485143 | Webler et al. | Feb 2009 | B2 |
| 7500989 | Solem et al. | Mar 2009 | B2 |
| 7503931 | Kowalsky et al. | Mar 2009 | B2 |
| 7510575 | Spenser et al. | Mar 2009 | B2 |
| 7527646 | Randert et al. | May 2009 | B2 |
| 7530995 | Quijano et al. | May 2009 | B2 |
| 7547321 | Silvestri et al. | Jun 2009 | B2 |
| 7549983 | Roue et al. | Jun 2009 | B2 |
| 7597703 | Sater | Oct 2009 | B2 |
| 7608102 | Adams et al. | Oct 2009 | B2 |
| 7618449 | Tremulis et al. | Nov 2009 | B2 |
| 7628797 | Tieu et al. | Dec 2009 | B2 |
| 7632303 | Stalker et al. | Dec 2009 | B1 |
| 7637946 | Solem et al. | Dec 2009 | B2 |
| 7666204 | Thornton et al. | Feb 2010 | B2 |
| 7695512 | Lashinski et al. | Apr 2010 | B2 |
| 7704277 | Zakay et al. | Apr 2010 | B2 |
| 7722523 | Mortier et al. | May 2010 | B2 |
| 7758632 | Hojeibane et al. | Jul 2010 | B2 |
| 7771467 | Svensson | Aug 2010 | B2 |
| 7780726 | Seguin | Aug 2010 | B2 |
| 7785366 | Maurer et al. | Aug 2010 | B2 |
| 7803187 | Hauser | Sep 2010 | B2 |
| 7806910 | Anderson | Oct 2010 | B2 |
| 7837727 | Goetz et al. | Nov 2010 | B2 |
| 7841502 | Walberg et al. | Nov 2010 | B2 |
| 7857846 | Alferness et al. | Dec 2010 | B2 |
| 7871433 | Lattouf | Jan 2011 | B2 |
| 7883539 | Schweich, Jr. et al. | Feb 2011 | B2 |
| 7892214 | Kagan et al. | Feb 2011 | B2 |
| 7947207 | Mcniven et al. | May 2011 | B2 |
| 7972378 | Tabor et al. | Jul 2011 | B2 |
| 7991484 | Sengupta et al. | Aug 2011 | B1 |
| 7992567 | Hirotsuka | Aug 2011 | B2 |
| 7993368 | Gambale et al. | Aug 2011 | B2 |
| 7993397 | Lashinski et al. | Aug 2011 | B2 |
| 8010207 | Smits et al. | Aug 2011 | B2 |
| 8025495 | Hardert et al. | Sep 2011 | B2 |
| 8029518 | Goldfarb et al. | Oct 2011 | B2 |
| 8052592 | Goldfarb et al. | Nov 2011 | B2 |
| 8075616 | Solem et al. | Dec 2011 | B2 |
| 8092517 | Kalmann et al. | Jan 2012 | B2 |
| 8092520 | Quadri | Jan 2012 | B2 |
| 8092525 | Eliasen et al. | Jan 2012 | B2 |
| 8100820 | Hauser et al. | Jan 2012 | B2 |
| 8108054 | Helland | Jan 2012 | B2 |
| 8109996 | Stacchino et al. | Feb 2012 | B2 |
| 8137381 | Foerster et al. | Mar 2012 | B2 |
| 8142493 | Spence et al. | Mar 2012 | B2 |
| 8142495 | Hasenkam et al. | Mar 2012 | B2 |
| 8147542 | Maisano et al. | Apr 2012 | B2 |
| 8157810 | Case et al. | Apr 2012 | B2 |
| 8197441 | Webler et al. | Jun 2012 | B2 |
| 8202281 | Voss | Jun 2012 | B2 |
| 8202315 | Hlavka et al. | Jun 2012 | B2 |
| 8216302 | Wilson et al. | Jul 2012 | B2 |
| 8226707 | White | Jul 2012 | B2 |
| 8236013 | Chu | Aug 2012 | B2 |
| 8236049 | Rowe et al. | Aug 2012 | B2 |
| 8252005 | Findlay et al. | Aug 2012 | B2 |
| 8262567 | Sharp et al. | Sep 2012 | B2 |
| 8262724 | Seguin et al. | Sep 2012 | B2 |
| 8262725 | Subramanian | Sep 2012 | B2 |
| 8267981 | Boock et al. | Sep 2012 | B2 |
| 8313497 | Walberg et al. | Nov 2012 | B2 |
| 8313498 | Pantages et al. | Nov 2012 | B2 |
| 8323312 | Clark | Dec 2012 | B2 |
| 8323335 | Rowe et al. | Dec 2012 | B2 |
| 8332051 | Sommer et al. | Dec 2012 | B2 |
| 8361088 | McIntosh | Jan 2013 | B2 |
| 8382829 | Call et al. | Feb 2013 | B1 |
| 8398672 | Kleshinski et al. | Mar 2013 | B2 |
| 8409273 | Thornton et al. | Apr 2013 | B2 |
| 8419753 | Stafford | Apr 2013 | B2 |
| 8430893 | Ma | Apr 2013 | B2 |
| 8449606 | Eliasen et al. | May 2013 | B2 |
| 8460368 | Taylor et al. | Jun 2013 | B2 |
| 8460371 | Hlavka et al. | Jun 2013 | B2 |
| 8475525 | Maisano et al. | Jul 2013 | B2 |
| 8480691 | Dana et al. | Jul 2013 | B2 |
| 8480730 | Maurer et al. | Jul 2013 | B2 |
| 8523881 | Cabiri et al. | Sep 2013 | B2 |
| 8524132 | Von Oepen et al. | Sep 2013 | B2 |
| 8529621 | Alfieri et al. | Sep 2013 | B2 |
| 8545553 | Zipory et al. | Oct 2013 | B2 |
| 8568475 | Nguyen et al. | Oct 2013 | B2 |
| 8568476 | Rao et al. | Oct 2013 | B2 |
| 8591460 | Wilson et al. | Nov 2013 | B2 |
| 8597347 | Maurer et al. | Dec 2013 | B2 |
| 8628569 | Benichou et al. | Jan 2014 | B2 |
| 8628571 | Hacohen | Jan 2014 | B1 |
| 8663248 | Zung et al. | Mar 2014 | B2 |
| 8685080 | White | Apr 2014 | B2 |
| 8685083 | Perier et al. | Apr 2014 | B2 |
| 8721588 | Echarri et al. | May 2014 | B2 |
| 8728097 | Sugimoto et al. | May 2014 | B1 |
| 8747463 | Fogarty et al. | Jun 2014 | B2 |
| 8753357 | Roorda et al. | Jun 2014 | B2 |
| 8753373 | Chau et al. | Jun 2014 | B2 |
| 8758402 | Jenson et al. | Jun 2014 | B2 |
| 8778017 | Eliasen et al. | Jul 2014 | B2 |
| 8784481 | Alkhatib et al. | Jul 2014 | B2 |
| 8790394 | Miller et al. | Jul 2014 | B2 |
| 8795356 | Quadri et al. | Aug 2014 | B2 |
| 8808366 | Braido et al. | Aug 2014 | B2 |
| 8808368 | Maisano et al. | Aug 2014 | B2 |
| 8845723 | Spence et al. | Sep 2014 | B2 |
| 8852270 | Maurer et al. | Oct 2014 | B2 |
| 8852272 | Gross et al. | Oct 2014 | B2 |
| 8858594 | Clark | Oct 2014 | B2 |
| 8858623 | Miller et al. | Oct 2014 | B2 |
| 8864822 | Spence et al. | Oct 2014 | B2 |
| 8870949 | Rowe | Oct 2014 | B2 |
| 8870950 | Hacohen | Oct 2014 | B2 |
| 8893947 | Reynolds et al. | Nov 2014 | B2 |
| 8911461 | Traynor et al. | Dec 2014 | B2 |
| 8926691 | Chau et al. | Jan 2015 | B2 |
| 8945177 | Dell et al. | Feb 2015 | B2 |
| 8945211 | Sugimoto | Feb 2015 | B2 |
| 8951285 | Sugimoto et al. | Feb 2015 | B2 |
| 8961594 | Maisano et al. | Feb 2015 | B2 |
| 8961595 | Alkhatib | Feb 2015 | B2 |
| 8961596 | Maisano et al. | Feb 2015 | B2 |
| 8968335 | Robinson et al. | Mar 2015 | B2 |
| 8968336 | Conklin et al. | Mar 2015 | B2 |
| 8968395 | Hauser et al. | Mar 2015 | B2 |
| 8979922 | Jayasinghe et al. | Mar 2015 | B2 |
| 8979923 | Spence et al. | Mar 2015 | B2 |
| 9005273 | Salahieh et al. | Apr 2015 | B2 |
| 9011468 | Ketai et al. | Apr 2015 | B2 |
| 9017347 | Oba et al. | Apr 2015 | B2 |
| 9034032 | McLean et al. | May 2015 | B2 |
| 9034033 | McLean et al. | May 2015 | B2 |
| 9078652 | Conklin et al. | Jul 2015 | B2 |
| 9084676 | Chau et al. | Jul 2015 | B2 |
| 9107749 | Bobo et al. | Aug 2015 | B2 |
| 9131939 | Call et al. | Sep 2015 | B1 |
| 9138335 | Cartledge et al. | Sep 2015 | B2 |
| 9180005 | Lashinski et al. | Nov 2015 | B1 |
| 9192471 | Bolling | Nov 2015 | B2 |
| 9211203 | Pike et al. | Dec 2015 | B2 |
| 9241702 | Maisano et al. | Jan 2016 | B2 |
| 9241706 | Paraschac et al. | Jan 2016 | B2 |
| 9259218 | Robinson | Feb 2016 | B2 |
| 9259317 | Wilson et al. | Feb 2016 | B2 |
| 9282965 | Kokish | Mar 2016 | B2 |
| 9289282 | Olson et al. | Mar 2016 | B2 |
| 9289297 | Wilson et al. | Mar 2016 | B2 |
| 9301749 | Rowe et al. | Apr 2016 | B2 |
| 9314242 | Bachman | Apr 2016 | B2 |
| 9326870 | Berglund et al. | May 2016 | B2 |
| 9358111 | Spence et al. | Jun 2016 | B2 |
| 9408607 | Cartledge et al. | Aug 2016 | B2 |
| 9474605 | Rowe et al. | Oct 2016 | B2 |
| 20020013571 | Goldfarb et al. | Jan 2002 | A1 |
| 20020032481 | Gabbay | May 2002 | A1 |
| 20020082625 | Huxel et al. | Jun 2002 | A1 |
| 20020107564 | Cox et al. | Aug 2002 | A1 |
| 20020151961 | Lashinski et al. | Oct 2002 | A1 |
| 20020156517 | Perouse | Oct 2002 | A1 |
| 20020177904 | Huxel et al. | Nov 2002 | A1 |
| 20030033003 | Harrison et al. | Feb 2003 | A1 |
| 20030057156 | Peterson et al. | Mar 2003 | A1 |
| 20030083742 | Spence et al. | May 2003 | A1 |
| 20030093096 | McGuckin, Jr. et al. | May 2003 | A1 |
| 20030167071 | Martin et al. | Sep 2003 | A1 |
| 20030229350 | Kay | Dec 2003 | A1 |
| 20030236568 | Hojeibane et al. | Dec 2003 | A1 |
| 20040117009 | Cali et al. | Jun 2004 | A1 |
| 20040133274 | Webler et al. | Jul 2004 | A1 |
| 20040158314 | Hogendijk | Aug 2004 | A1 |
| 20040172046 | Hlavka et al. | Sep 2004 | A1 |
| 20040181287 | Gellman | Sep 2004 | A1 |
| 20040186566 | Hindrichs et al. | Sep 2004 | A1 |
| 20040193092 | Deal | Sep 2004 | A1 |
| 20040236419 | Milo | Nov 2004 | A1 |
| 20040260389 | Case et al. | Dec 2004 | A1 |
| 20050004668 | Aklog et al. | Jan 2005 | A1 |
| 20050016560 | Voughlohn | Jan 2005 | A1 |
| 20050021085 | Abrams et al. | Jan 2005 | A1 |
| 20050055089 | Macoviak et al. | Mar 2005 | A1 |
| 20050059997 | Bauman et al. | Mar 2005 | A1 |
| 20050075713 | Biancucci et al. | Apr 2005 | A1 |
| 20050075723 | Schroeder et al. | Apr 2005 | A1 |
| 20050080483 | Solem et al. | Apr 2005 | A1 |
| 20050090827 | Gedebou | Apr 2005 | A1 |
| 20050107812 | Starksen et al. | May 2005 | A1 |
| 20050107871 | Realyvasquez et al. | May 2005 | A1 |
| 20050113900 | Shiroff et al. | May 2005 | A1 |
| 20050125077 | Harmon et al. | Jun 2005 | A1 |
| 20050137686 | Salahieh et al. | Jun 2005 | A1 |
| 20050137688 | Salahieh et al. | Jun 2005 | A1 |
| 20050137695 | Salahieh et al. | Jun 2005 | A1 |
| 20050154448 | Cully et al. | Jul 2005 | A1 |
| 20050177180 | Kaganov et al. | Aug 2005 | A1 |
| 20050177224 | Fogarty et al. | Aug 2005 | A1 |
| 20050177228 | Solem | Aug 2005 | A1 |
| 20050203606 | VanCamp | Sep 2005 | A1 |
| 20050216039 | Lederman | Sep 2005 | A1 |
| 20050216079 | MaCoviak | Sep 2005 | A1 |
| 20050222665 | Arayani | Oct 2005 | A1 |
| 20050251208 | Elmer et al. | Nov 2005 | A1 |
| 20050256532 | Nayak et al. | Nov 2005 | A1 |
| 20050273138 | To et al. | Dec 2005 | A1 |
| 20050283246 | Cauthen et al. | Dec 2005 | A1 |
| 20060004442 | Spenser et al. | Jan 2006 | A1 |
| 20060020326 | Bolduc et al. | Jan 2006 | A9 |
| 20060020327 | Lashinski et al. | Jan 2006 | A1 |
| 20060052821 | Abbot et al. | Mar 2006 | A1 |
| 20060106420 | Dolan et al. | May 2006 | A1 |
| 20060106423 | Weisel et al. | May 2006 | A1 |
| 20060129166 | Lavelle | Jun 2006 | A1 |
| 20060161265 | Levine et al. | Jul 2006 | A1 |
| 20060173524 | Salahieh et al. | Aug 2006 | A1 |
| 20060178700 | Quinn | Aug 2006 | A1 |
| 20060200199 | Bonutti et al. | Sep 2006 | A1 |
| 20060229708 | Powell et al. | Oct 2006 | A1 |
| 20060241745 | Solem | Oct 2006 | A1 |
| 20060241748 | Lee et al. | Oct 2006 | A1 |
| 20060259135 | Navia et al. | Nov 2006 | A1 |
| 20060259137 | Artof et al. | Nov 2006 | A1 |
| 20060276871 | Lamson et al. | Dec 2006 | A1 |
| 20060282161 | Huynh et al. | Dec 2006 | A1 |
| 20070016287 | Cartledge | Jan 2007 | A1 |
| 20070016288 | Gurskis | Jan 2007 | A1 |
| 20070021781 | Jervis et al. | Jan 2007 | A1 |
| 20070032787 | Hassett et al. | Feb 2007 | A1 |
| 20070038221 | Fine et al. | Feb 2007 | A1 |
| 20070038296 | Navia | Feb 2007 | A1 |
| 20070049942 | Hindrichs et al. | Mar 2007 | A1 |
| 20070049970 | Belef et al. | Mar 2007 | A1 |
| 20070051377 | Douk et al. | Mar 2007 | A1 |
| 20070055340 | Pryor | Mar 2007 | A1 |
| 20070060895 | Sibbitt et al. | Mar 2007 | A1 |
| 20070060989 | Deem et al. | Mar 2007 | A1 |
| 20070061010 | Hauser et al. | Mar 2007 | A1 |
| 20070066863 | Rafiee et al. | Mar 2007 | A1 |
| 20070083168 | Whiting et al. | Apr 2007 | A1 |
| 20070093869 | Bloom et al. | Apr 2007 | A1 |
| 20070100427 | Perouse | May 2007 | A1 |
| 20070112425 | Schaller et al. | May 2007 | A1 |
| 20070118151 | Davidson | May 2007 | A1 |
| 20070123936 | Goldin et al. | May 2007 | A1 |
| 20070162107 | Haug et al. | Jul 2007 | A1 |
| 20070168013 | Douglas | Jul 2007 | A1 |
| 20070185532 | Stone et al. | Aug 2007 | A1 |
| 20070198082 | Kapadia et al. | Aug 2007 | A1 |
| 20070203391 | Bloom et al. | Aug 2007 | A1 |
| 20070208389 | Amundson et al. | Sep 2007 | A1 |
| 20070219558 | Deutsch | Sep 2007 | A1 |
| 20070250160 | Rafiee | Oct 2007 | A1 |
| 20070265700 | Eliasen et al. | Nov 2007 | A1 |
| 20070270943 | Solem et al. | Nov 2007 | A1 |
| 20070276437 | Call et al. | Nov 2007 | A1 |
| 20070276467 | Kalmann | Nov 2007 | A1 |
| 20070282375 | Hindrichs et al. | Dec 2007 | A1 |
| 20070282429 | Hauser et al. | Dec 2007 | A1 |
| 20070288086 | Kalmann et al. | Dec 2007 | A1 |
| 20070288089 | Gurskis et al. | Dec 2007 | A1 |
| 20080003539 | Lundgren | Jan 2008 | A1 |
| 20080015617 | Harari et al. | Jan 2008 | A1 |
| 20080027268 | Buckner et al. | Jan 2008 | A1 |
| 20080027446 | Stone et al. | Jan 2008 | A1 |
| 20080027483 | Cartledge | Jan 2008 | A1 |
| 20080035160 | Woodson et al. | Feb 2008 | A1 |
| 20080058866 | Young et al. | Mar 2008 | A1 |
| 20080077231 | Heringes et al. | Mar 2008 | A1 |
| 20080097595 | Gabbay | Apr 2008 | A1 |
| 20080125861 | Webler et al. | May 2008 | A1 |
| 20080140116 | Bonutti | Jun 2008 | A1 |
| 20080140188 | Randert et al. | Jun 2008 | A1 |
| 20080167714 | St. Goar | Jul 2008 | A1 |
| 20080190989 | Crews et al. | Aug 2008 | A1 |
| 20080262598 | Elmaleh | Oct 2008 | A1 |
| 20080262609 | Gross et al. | Oct 2008 | A1 |
| 20080275469 | Fanton et al. | Nov 2008 | A1 |
| 20080281411 | Berreklouw et al. | Nov 2008 | A1 |
| 20080288044 | Osborne | Nov 2008 | A1 |
| 20080288062 | Andrieu et al. | Nov 2008 | A1 |
| 20080300629 | Surti | Dec 2008 | A1 |
| 20090005863 | Goetz et al. | Jan 2009 | A1 |
| 20090043382 | Maurer et al. | Feb 2009 | A1 |
| 20090048668 | Wilson et al. | Feb 2009 | A1 |
| 20090082828 | Ostroff | Mar 2009 | A1 |
| 20090082847 | Zacharias et al. | Mar 2009 | A1 |
| 20090084386 | McClellan et al. | Apr 2009 | A1 |
| 20090099647 | Glimsdale et al. | Apr 2009 | A1 |
| 20090099649 | Chobotov et al. | Apr 2009 | A1 |
| 20090112052 | Lund et al. | Apr 2009 | A1 |
| 20090118776 | Kelsch et al. | May 2009 | A1 |
| 20090131849 | Maurer et al. | May 2009 | A1 |
| 20090132033 | Maurer et al. | May 2009 | A1 |
| 20090143808 | Houser | Jun 2009 | A1 |
| 20090149872 | Gross et al. | Jun 2009 | A1 |
| 20090171439 | Nis Sl | Jul 2009 | A1 |
| 20090216265 | DeVries | Aug 2009 | A1 |
| 20090240326 | Wilson et al. | Sep 2009 | A1 |
| 20090254103 | Deutsch et al. | Oct 2009 | A1 |
| 20090259307 | Gross et al. | Oct 2009 | A1 |
| 20090264991 | Paul et al. | Oct 2009 | A1 |
| 20090264995 | Subramanian | Oct 2009 | A1 |
| 20090276040 | Rowe et al. | Nov 2009 | A1 |
| 20090287304 | Dahlgren et al. | Nov 2009 | A1 |
| 20090306622 | Machold et al. | Dec 2009 | A1 |
| 20090326648 | Machold et al. | Dec 2009 | A1 |
| 20100010620 | Weber | Jan 2010 | A1 |
| 20100022948 | Wilson et al. | Jan 2010 | A1 |
| 20100023117 | Yoganathan et al. | Jan 2010 | A1 |
| 20100023118 | Medlock et al. | Jan 2010 | A1 |
| 20100029071 | Russell et al. | Feb 2010 | A1 |
| 20100030329 | Frater | Feb 2010 | A1 |
| 20100049293 | Zukowski et al. | Feb 2010 | A1 |
| 20100063520 | Bilotti | Mar 2010 | A1 |
| 20100063542 | Van der Burg et al. | Mar 2010 | A1 |
| 20100063586 | Hasenkam et al. | Mar 2010 | A1 |
| 20100121349 | Meier et al. | May 2010 | A1 |
| 20100121434 | Paul et al. | May 2010 | A1 |
| 20100121435 | Subramanian et al. | May 2010 | A1 |
| 20100130992 | Machold et al. | May 2010 | A1 |
| 20100161041 | Maisano et al. | Jun 2010 | A1 |
| 20100161042 | Maisano et al. | Jun 2010 | A1 |
| 20100161043 | Maisano et al. | Jun 2010 | A1 |
| 20100161047 | Cabiri | Jun 2010 | A1 |
| 20100168791 | Kassab | Jul 2010 | A1 |
| 20100174358 | Rabkin | Jul 2010 | A1 |
| 20100185278 | Schankereli | Jul 2010 | A1 |
| 20100204662 | Orlov et al. | Aug 2010 | A1 |
| 20100211166 | Miller et al. | Aug 2010 | A1 |
| 20100217309 | Hansen et al. | Aug 2010 | A1 |
| 20100217382 | Chau et al. | Aug 2010 | A1 |
| 20100228269 | Garrison et al. | Sep 2010 | A1 |
| 20100234935 | Bashiri | Sep 2010 | A1 |
| 20100249908 | Chau et al. | Sep 2010 | A1 |
| 20100249920 | Bolling et al. | Sep 2010 | A1 |
| 20100256743 | Hinchliffe et al. | Oct 2010 | A1 |
| 20100264192 | Marczyk | Oct 2010 | A1 |
| 20100268204 | Tieu et al. | Oct 2010 | A1 |
| 20100274276 | Chow | Oct 2010 | A1 |
| 20100280603 | Maisano et al. | Nov 2010 | A1 |
| 20100280604 | Zipory et al. | Nov 2010 | A1 |
| 20100280605 | Hammer et al. | Nov 2010 | A1 |
| 20100286628 | Gross | Nov 2010 | A1 |
| 20100286767 | Zipory et al. | Nov 2010 | A1 |
| 20100298930 | Orlov | Nov 2010 | A1 |
| 20100324598 | Anderson | Dec 2010 | A1 |
| 20100324668 | Maurer et al. | Dec 2010 | A1 |
| 20110004296 | Lutter et al. | Jan 2011 | A1 |
| 20110009818 | Goff | Jan 2011 | A1 |
| 20110011917 | Loulmet | Jan 2011 | A1 |
| 20110022164 | Quinn et al. | Jan 2011 | A1 |
| 20110029066 | Gilad | Feb 2011 | A1 |
| 20110029071 | Zlotnick et al. | Feb 2011 | A1 |
| 20110035000 | Nieminen et al. | Feb 2011 | A1 |
| 20110040366 | Goetz et al. | Feb 2011 | A1 |
| 20110071626 | Wright et al. | Mar 2011 | A1 |
| 20110077733 | Solem | Mar 2011 | A1 |
| 20110082538 | Dahlgren et al. | Apr 2011 | A1 |
| 20110087146 | Ryan et al. | Apr 2011 | A1 |
| 20110092993 | Jacobs | Apr 2011 | A1 |
| 20110093002 | Rucker et al. | Apr 2011 | A1 |
| 20110098732 | Jacobs | Apr 2011 | A1 |
| 20110106245 | Miller et al. | May 2011 | A1 |
| 20110106247 | Miller et al. | May 2011 | A1 |
| 20110112619 | Foster et al. | May 2011 | A1 |
| 20110112632 | Chau et al. | May 2011 | A1 |
| 20110137397 | Chau et al. | Jun 2011 | A1 |
| 20110152998 | Berez et al. | Jun 2011 | A1 |
| 20110166636 | Rowe | Jul 2011 | A1 |
| 20110184510 | Maisano | Jul 2011 | A1 |
| 20110190879 | Tsukashima et al. | Aug 2011 | A1 |
| 20110208283 | Rust et al. | Aug 2011 | A1 |
| 20110224785 | Hacohen | Sep 2011 | A1 |
| 20110238088 | Bolduc et al. | Sep 2011 | A1 |
| 20110238112 | Kim et al. | Sep 2011 | A1 |
| 20110251678 | Eidenschink | Oct 2011 | A1 |
| 20110264208 | Duffy et al. | Oct 2011 | A1 |
| 20110301698 | Miller et al. | Dec 2011 | A1 |
| 20120016343 | Gill | Jan 2012 | A1 |
| 20120022633 | Olson et al. | Jan 2012 | A1 |
| 20120022639 | Hacohen et al. | Jan 2012 | A1 |
| 20120022640 | Gross et al. | Jan 2012 | A1 |
| 20120143320 | Eliasen et al. | Jan 2012 | A1 |
| 20120029628 | Rowe | Feb 2012 | A1 |
| 20120035712 | Maisano | Feb 2012 | A1 |
| 20120083806 | Goertzen | Apr 2012 | A1 |
| 20120123531 | Tsukashima et al. | May 2012 | A1 |
| 20120130374 | Bouduban et al. | May 2012 | A1 |
| 20120130421 | Hafez et al. | May 2012 | A1 |
| 20120158053 | Paulos | Jun 2012 | A1 |
| 20120179244 | Schankereli et al. | Jul 2012 | A1 |
| 20120215236 | Matsunaga et al. | Aug 2012 | A1 |
| 20120222969 | Osborne et al. | Sep 2012 | A1 |
| 20120226349 | Tuval et al. | Sep 2012 | A1 |
| 20120232373 | Hallander et al. | Sep 2012 | A1 |
| 20120245604 | Tegzes | Sep 2012 | A1 |
| 20120283757 | Miller et al. | Nov 2012 | A1 |
| 20120296349 | Smith et al. | Nov 2012 | A1 |
| 20120310328 | Olson et al. | Dec 2012 | A1 |
| 20130030522 | Rowe et al. | Jan 2013 | A1 |
| 20130041459 | Wilson et al. | Feb 2013 | A1 |
| 20130046373 | Cartledge | Feb 2013 | A1 |
| 20130053951 | Baliarda | Feb 2013 | A1 |
| 20130079873 | Migliazza et al. | Mar 2013 | A1 |
| 20130085529 | Housman | Apr 2013 | A1 |
| 20130096664 | Goetz et al. | Apr 2013 | A1 |
| 20130096672 | Reich et al. | Apr 2013 | A1 |
| 20130110230 | Solem | May 2013 | A1 |
| 20130166017 | Cartledge et al. | Jun 2013 | A1 |
| 20130166022 | Conklin | Jun 2013 | A1 |
| 20130172978 | Vidlund et al. | Jul 2013 | A1 |
| 20130281760 | Farnan et al. | Oct 2013 | A1 |
| 20130296925 | Chanduszko et al. | Nov 2013 | A1 |
| 20130325110 | Khalil et al. | Dec 2013 | A1 |
| 20130331930 | Rowe et al. | Dec 2013 | A1 |
| 20140005778 | Buchbinder et al. | Jan 2014 | A1 |
| 20140018911 | Zhou et al. | Jan 2014 | A1 |
| 20140031864 | Jafari et al. | Jan 2014 | A1 |
| 20140031928 | Murphy et al. | Jan 2014 | A1 |
| 20140058405 | Foster | Feb 2014 | A1 |
| 20140066693 | Goldfarb et al. | Mar 2014 | A1 |
| 20140067054 | Chau et al. | Mar 2014 | A1 |
| 20140114390 | Tobis et al. | Apr 2014 | A1 |
| 20140121763 | Duffy et al. | May 2014 | A1 |
| 20140142689 | De Canniere et al. | May 2014 | A1 |
| 20140163690 | White | Jun 2014 | A1 |
| 20140200657 | Maurer et al. | Jul 2014 | A1 |
| 20140207231 | Hacohen et al. | Jul 2014 | A1 |
| 20140214159 | Vidlund et al. | Jul 2014 | A1 |
| 20140243894 | Groothuis et al. | Aug 2014 | A1 |
| 20140257475 | Gross et al. | Sep 2014 | A1 |
| 20140275757 | Goodwin et al. | Sep 2014 | A1 |
| 20140277390 | Ratz et al. | Sep 2014 | A1 |
| 20140277427 | Ratz et al. | Sep 2014 | A1 |
| 20140288639 | Gainor | Sep 2014 | A1 |
| 20140296962 | Cartledge et al. | Oct 2014 | A1 |
| 20140309730 | Alon et al. | Oct 2014 | A1 |
| 20140324164 | Gross et al. | Oct 2014 | A1 |
| 20140358224 | Tegels et al. | Dec 2014 | A1 |
| 20140371843 | Wilson et al. | Dec 2014 | A1 |
| 20140379006 | Sutherland et al. | Dec 2014 | A1 |
| 20140379074 | Spence et al. | Dec 2014 | A1 |
| 20140379076 | Vidlund et al. | Dec 2014 | A1 |
| 20150018940 | Quill et al. | Jan 2015 | A1 |
| 20150045879 | Longoria et al. | Feb 2015 | A1 |
| 20150051698 | Baliarda et al. | Feb 2015 | A1 |
| 20150066138 | Alexander et al. | Mar 2015 | A1 |
| 20150073545 | Braido | Mar 2015 | A1 |
| 20150094800 | Chawla | Apr 2015 | A1 |
| 20150094802 | Buchbinder et al. | Apr 2015 | A1 |
| 20150100116 | Mohl et al. | Apr 2015 | A1 |
| 20150119936 | Gilmore et al. | Apr 2015 | A1 |
| 20150127097 | Neumann et al. | May 2015 | A1 |
| 20150142049 | Delgado et al. | May 2015 | A1 |
| 20150142103 | Vidlund | May 2015 | A1 |
| 20150142105 | Bolling et al. | May 2015 | A1 |
| 20150157329 | Rudakov et al. | Jun 2015 | A1 |
| 20150182336 | Zipory et al. | Jul 2015 | A1 |
| 20150196693 | Lin | Jul 2015 | A1 |
| 20150223934 | Vidlund et al. | Aug 2015 | A1 |
| 20150250590 | Gries et al. | Sep 2015 | A1 |
| 20150272730 | Melnick et al. | Oct 2015 | A1 |
| 20150320414 | Conklin et al. | Nov 2015 | A1 |
| 20150351903 | Morriss | Dec 2015 | A1 |
| 20150351909 | Bobo et al. | Dec 2015 | A1 |
| 20150366666 | Khairkhahan et al. | Dec 2015 | A1 |
| 20160022417 | Karapetian et al. | Jan 2016 | A1 |
| 20160038285 | Glenn et al. | Feb 2016 | A1 |
| 20160081829 | Rowe | Mar 2016 | A1 |
| 20160120672 | Martin et al. | May 2016 | A1 |
| 20160128689 | Sutherland et al. | May 2016 | A1 |
| 20160157862 | Hernandez et al. | Jun 2016 | A1 |
| 20160174979 | Wei | Jun 2016 | A1 |
| 20160228246 | Zimmerman | Aug 2016 | A1 |
| 20160228252 | Keidar | Aug 2016 | A1 |
| 20160235526 | Lashinski et al. | Aug 2016 | A1 |
| 20160256269 | Cahalane et al. | Sep 2016 | A1 |
| 20160270776 | Miraki et al. | Sep 2016 | A1 |
| 20160270916 | Cahalane et al. | Sep 2016 | A1 |
| 20160287383 | Rowe | Oct 2016 | A1 |
| 20160287387 | Wei | Oct 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 102007043830 | Apr 2009 | DE |
| 1568326 | Aug 2005 | EP |
| 1397176 | Mar 2007 | EP |
| 1759663 | Mar 2007 | EP |
| 1 836 971 | Sep 2007 | EP |
| 1562522 | Dec 2008 | EP |
| 1357843 | May 2009 | EP |
| 1 968 491 | Jul 2010 | EP |
| 1928357 | Nov 2010 | EP |
| 1718249 | Apr 2011 | EP |
| 2399549 | Mar 2014 | EP |
| 1646332 | Jun 2015 | EP |
| 2410948 | Jul 2016 | EP |
| 2465568 | Aug 2016 | EP |
| 2023858 | Oct 2016 | EP |
| 1992005093 | Apr 1992 | WO |
| 1997041778 | Nov 1997 | WO |
| 200028923 | May 2000 | WO |
| 2001010306 | Feb 2001 | WO |
| 2004069055 | Aug 2004 | WO |
| 2004082538 | Sep 2004 | WO |
| 2005021063 | Mar 2005 | WO |
| 2005058206 | Jun 2005 | WO |
| 2005102194 | Nov 2005 | WO |
| 2006019498 | Feb 2006 | WO |
| 2006034062 | Mar 2006 | WO |
| 2006097931 | Sep 2006 | WO |
| 2006105008 | Oct 2006 | WO |
| 2006105009 | Oct 2006 | WO |
| 2007080595 | Jul 2007 | WO |
| 2007140309 | Dec 2007 | WO |
| 2008065044 | Jun 2008 | WO |
| 2008068756 | Jun 2008 | WO |
| 2009039400 | Mar 2009 | WO |
| 2009101617 | Aug 2009 | WO |
| 2010004546 | Jan 2010 | WO |
| 2010008549 | Jan 2010 | WO |
| 2010071494 | Jun 2010 | WO |
| 2010073246 | Jul 2010 | WO |
| 2010099032 | Sep 2010 | WO |
| 2010108079 | Sep 2010 | WO |
| 2010128502 | Nov 2010 | WO |
| 2010128503 | Nov 2010 | WO |
| 2011014496 | Feb 2011 | WO |
| 2011037891 | Mar 2011 | WO |
| 2011051942 | May 2011 | WO |
| 2011089601 | Jul 2011 | WO |
| 2011097355 | Aug 2011 | WO |
| 2011143263 | Nov 2011 | WO |
| 2011153408 | Dec 2011 | WO |
| 2012127309 | Sep 2012 | WO |
| 2013003228 | Jan 2013 | WO |
| 2013011502 | Jan 2013 | WO |
| 2013028145 | Feb 2013 | WO |
| 2013078497 | Jun 2013 | WO |
| 2014043527 | Mar 2014 | WO |
| 2014064694 | May 2014 | WO |
| 2014087402 | Jun 2014 | WO |
| 2014108903 | Jul 2014 | WO |
| 2014141239 | Sep 2014 | WO |
| 2015015497 | Feb 2015 | WO |
| 2015063580 | May 2015 | WO |
| 2015193728 | Dec 2015 | WO |
| 2016011275 | Jan 2016 | WO |
| 2016087934 | Jun 2016 | WO |
| Entry |
|---|
| A non-final office action in U.S. Appl. No. 13/574,088, dated Mar. 23, 2017. |
| Communication dated Jun. 23, 2016 from the State Intellectual Property Office of the P.R.C. in counterpart Application No. 201480028044.3. |
| Communication dated Sep. 5, 2016 from the State Intellectual Property Office of the P.R.C. in counterpart Application No. 201480028044.3. |
| An Office Action dated Sep. 16, 2016, which issued during the prosecution of U.S. Appl. No. 13/574,088. |
| Invitation to pay additional fees in PCT/IB2006/000840 dated Oct. 13, 2016. |
| An Interview Summary dated Dec. 5, 2016, which issued during the prosecution of U.S. Appl. No. 13/574,088. |
| An International Search Report and a Written Opinion both dated Apr. 15, 2016, which issued during the prosecution of Applicant's PCT/IB2015/002354. |
| An Office Action dated May 11, 2016, which issued during the prosecution of U.S. Appl. No. 13/574,088. |
| An International Search Report and a Written Opinion both dated Dec. 6, 2013, which issued during the prosecution of Applicant's PCT/IL2013/050470. |
| U.S. Appl. No. 61/783,224, filed Mar. 14, 2013. |
| Alfieri et al., “An effective technique to correct anterior mitral leaflet prolapse,” J Card Surg 14(6):468-470 (1999). |
| Alfieri et al., “Novel suture device for beating heart mitral leaflet approximation,” Annals of Thoracic Surgery 74:1488 1493 (2002). |
| Alfieri et al., “The double orifice technique in mitral valve repair: a simple solution for complex problems,” Journal of Thoracic Cardiovascular Surgery 122:674-681 (2001). |
| Amplatzer Cardiac Plug Brochure (English Pages), AGA Medical Corporation, Plymouth, MN Copyright 2008-2011, downloaded Jan. 11, 2011. |
| Beale BS, “Surgical Repair of Collateral Ligament Injuries,” presented at 63rd CVMA Convention, Halifax, Nova Scotia, Canada, Jul. 6-9, 2011. |
| Dentistry Today, “Implant Direct” product information page, Jun. 1, 2011, downloaded Dec. 10, 2012 from http://dentistrytoday.com/top25implant-i/5558-implant-direct. |
| Maisano et al., “The double-orifice technique as a standardized approach to treat mitral regurgitation due to severe myxomatous disease: surgical technique,” European Journal of Cardio-thoracic Surgery 17 (2000) 201-205. |
| Shikhar Agarwal et al., “Interventional Cardiology Perspective of Functional Tricuspid Regurgitation,” Circulatoin: Cardiovascular Interventions, pp. 565-573; Dec. 2009; vol. 2, Issue 6. |
| Smith & Nephew MINITACTM™ TI 2.0 Suture Anchor Product Description, downloaded on Dec. 9, 2012 from http://global.smith-nephew.com/us/MINITAC—TI—2—SUTURE—ANCHR—3127.htm. |
| Second Notice of Allowance dated May 10, 2013, which issued during the prosecution of U.S. Appl. No. 12/692,061. |
| An Interview Summary dated Oct. 24, 2012, which issued during the prosecution of U.S. Appl. No. 12/692,061. |
| An Office Action dated Jul. 6, 2012, which issued during the prosecution of U.S. Appl. No. 12/692,061. |
| A Notice of Allowance dated Mar. 6, 2013, which issued during the prosecution of U.S. Appl. No. 12/692,061. |
| An International Search Report and a Written Opinion both dated May 19, 2011, which issued during the prosecution of Applicant's PCT/IL11/00064. |
| An International Search Report and a Written Opinion both dated Jan. 22, 2013, which issued during the prosecution of Applicant's PCT/IL2012/000282. |
| An Office Action dated Dec. 5, 2013, which issued during the prosecution of U.S. Appl. No. 13/485,145. |
| An International Search Report and a Written Opinion both dated Mar. 17, 2014, which issued during the prosecution of Applicant's PCT/IL2013/050937. |
| Invitation to pay additional fees in PCT/IL2014/050027 dated Apr. 4, 2014. |
| An International Search Report and a Written Opinion both dated May 28, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050027. |
| U.S. Appl. No. 60/902,146, filed Feb. 16, 2007. |
| European Search Report dated Apr. 10, 2015, which issued during the prosecution of Applicant's European App No. 11734451.5. |
| European Search Report dated May 15, 2015, which issued during the prosecution of Applicant's European App No. 12814417.7. |
| An Office Action dated Sep. 14, 2015, which issued during the prosecution of U.S. Appl. No. 13/553,081. |
| An English Translation of an Office Action dated Jun. 30, 2014 which issued during the prosecution of Chinese Patent Application No. 201180015301.6. |
| An English Translation of an Office Action dated Jul. 7, 2015 which issued during the prosecution of Japanese Patent Application No. 2012-549463. |
| An Office Action dated Oct. 7, 2015, which issued during the prosecution of U.S. Appl. No. 13/574,088. |
| Invitation to Pay Additional Fees dated Apr. 20, 2015, which issued during the prosecution of Applicant's PCT/IB2014/002351. |
| An International Search Report and a Written Opinion both dated Jun. 10, 2015, which issued during the prosecution of Applicant's PCT/IB2014/002351. |
| An Office Action dated Feb. 2, 2015, which issued during the prosecution of U.S. Appl. No. 14/143,355. |
| An English Translation of an Office Action dated Feb. 10, 2015 which issued during the prosecution of Chinese Patent Application No. 201180015301.6. |
| An Office Action dated Feb. 25, 2015, which issued during the prosecution of U.S. Appl. No. 13/574,088. |
| Notice of Allowance dated Sep. 24, 2015, which issued during the prosecution of U.S. Appl. No. 14/143,355. |
| Notice of Allowance dated Dec. 4, 2015, which issued during the prosecution of U.S. Appl. No. 14/143,355. |
| An Office Action dated Jul. 7, 2014, which issued during the prosecution of U.S. Appl. No. 13/485,145. |
| An Office Action dated Sep. 25, 2014, which issued during the prosecution of U.S. Appl. No. 13/485,145. |
| An English Translation of an Office Action dated Oct. 28, 2014,which issued during the prosecution of Japanese Patent Application No. 2012-549463. |
| Notice of Allowance dated Dec. 9, 2014, which issued during the prosecution of U.S. Appl. No. No. 13/485,145. |
| An International Search Report and a Written Opinion both dated Jun. 30, 2014, which issued during the prosecution of Applicant's PCT/IL2014/050233. |
| An International Search Report and a Written Opinion both dated Jan. 8, 2016, which issued during the prosecution of Applicant's PCT/IB2015/001196. |
| Invitation to pay additional fees in PCT/IB2015/001196 dated Oct. 26, 2015. |
| Notice of Allowance dated Dec. 4, 2014, which issued during the prosecution of U.S. Appl. No. 13/188,175. |
| An Office Action dated Nov. 25, 2014, which issued during the prosecution of U.S. Appl. No. 13/553,081. |
| An Office Action dated Apr. 18, 2016, which issued during the prosecution of U.S. Appl. No. 14/584,286. |
| Spinal & Epidural Needles—downloaded on Feb. 18, 2016 from http://www.cothon.net/Anestesia—Obstetrica/Neuroaxial—needles.html. |
| Japanese Patent Office, Dec. 18, 2017 Office Action, JP Patent Application 563548/2015 (dated Dec. 26, 2017). |
| Number | Date | Country | |
|---|---|---|---|
| 20160022448 A1 | Jan 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61783224 | Mar 2013 | US |
